Trial Profile
A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination With Intramuscular (IM) Fulvestrant to Patients With Estrogen Receptor Positive (ER+) Advanced, Metastatic Breast Cancer
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Fulvestrant (Primary) ; Vistusertib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; Pharmacokinetics
- Sponsors AstraZeneca
- 05 Jan 2024 Planned End Date changed from 29 Dec 2023 to 5 Sep 2028.
- 21 Mar 2023 Planned End Date changed from 30 Dec 2022 to 29 Dec 2023.
- 17 Jan 2022 Planned End Date changed from 31 Dec 2021 to 30 Dec 2022.